DoD VRP, Investigator-Initiated Research Award | HT942524VRPIIRA

Opportunity Information: Apply for HT942524VRPIIRA

The Department of Defense Vision Research Program (VRP) Investigator-Initiated Research Award (IIRA), managed by the U.S. Army Medical Research Acquisition Activity (USAMRAA), is a discretionary grant opportunity (CFDA 12.420) aimed at driving major advances in understanding, treating, and improving patient care for eye injury and visual dysfunction tied to military exposures. The emphasis is on work that can realistically move the field forward in a meaningful way, whether that means uncovering new biological insights, creating better diagnostic approaches, developing research tools that open up new lines of inquiry, or strengthening the path toward practical clinical translation for service members, veterans, and other affected populations.

A key feature of this program is that it offers two distinct funding levels to support projects at different stages of maturity, and applicants must choose the level that best matches the development stage of the idea rather than simply selecting based on desired budget size. Funding Level 1 is meant for early-stage, exploratory research that is intentionally high-risk and high-reward. It is designed for innovative concepts that could reshape thinking or create new directions for the field, such as entirely new approaches, tools, or research paradigms. Preliminary data are not required at this level, but the proposal still needs a strong scientific rationale grounded in existing literature. Importantly, researchers who do not have an established track record specifically in the visual system are still encouraged to apply under Funding Level 1, as long as the overall team has the expertise needed to properly test and execute the proposed idea.

Funding Level 2 is intended for more mature efforts where the foundational idea is already sufficiently developed and the next step is to push it further toward clinical relevance or translation. Projects at this level can span the spectrum from basic research through translational research, but they must be supported by preliminary data that demonstrate feasibility and readiness. While the work should be innovative or novel, the program also allows projects that offer significant improvements, refinements, or new applications of existing solutions, as long as the advancement is substantial and clearly justified. Funding Level 2 also includes an optional Partnering PI structure, allowing two principal investigators to formally lead the project. In that setup, one investigator is designated as the Initiating PI and handles most submission-related administrative responsibilities, while the Partnering PI plays a meaningful, substantial role in the design and execution of the research. If funded, each PI is named on a separate award issued to their respective organization(s), and each award carries its own reporting, regulatory, and administrative requirements.

The opportunity permits research involving human subjects and human anatomical substances, but it does not allow clinical trials. The program uses the federal regulatory definition of a clinical trial from 45 CFR 46.102: a study in which human subjects are prospectively assigned to an intervention (including placebo or control) to evaluate effects on biomedical or behavioral health-related outcomes. Work that analyzes data from clinical trials that were already conducted, especially retrospective analyses, is not considered a clinical trial under this announcement and may be allowable. The program draws a clear line between disallowed clinical trials and allowed clinical research, which it frames as observational work involving human data, specimens, or interaction with participants where the investigator is not evaluating intervention safety, efficacy, or effectiveness. Examples of allowable clinical research include studies on mechanisms of human disease, diagnostic or detection work such as biomarkers or imaging, health disparities research, technology development, epidemiologic or behavioral studies that do not test interventions, and outcomes or health services research that does not meet the clinical trial definition. The announcement also clarifies that certain in vitro studies using human data or specimens that cannot be linked to a living individual may fall under Common Rule exemptions (specifically 45 CFR 46.104(d)(4)), meaning they are treated differently from human subjects research that involves identifiable individuals.

Administratively, the opportunity is listed as open to unrestricted eligible applicants, with an original closing date of November 8, 2024. The Army (USAMRAA) is the sponsoring agency, and the program anticipates making about seven awards. Overall, the IIRA is structured to accommodate both bold, early concepts and later-stage, data-backed projects, as long as the work targets vision problems connected to military exposure and is positioned to deliver high-impact scientific or patient-care advancements without crossing into prospective interventional clinical trial territory.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD VRP, Investigator-Initiated Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-05-16.
• Applicants must submit their applications by 2024-11-08. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 7 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524VRPIIRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: